Sector News

Roche rejoins APBI

September 5, 2016
Life sciences

Swiss drugs giant Roche is rejoining the Association of the British Pharmaceutical Industry after cutting ties with the trade body seven years ago.

In June 2009 the firm announced that it would not be renewing its ABPI membership, citing a need to review its relationship with the organisation.

The move came after Roche had its membership suspended for six months in connection with “serious breaches” of the Association’s Code of Practice, relating to the inappropriate sale of large quantities of its weight-loss drug Xenical (orlistat) to an operator of private diet clinics.

Now, commenting on the firm’s renewed membership, Richard Erwin, General Manager of Roche Products, said: “Our industry can be subject to significant environmental shifts and we recognise how important it will be to collaborate with other companies, the NHS and healthcare professionals to ensure that UK patients can get access to world leading healthcare.”

“We are absolutely delighted to welcome Roche to the ABPI,” said its chief executive Mike Thompson. “This is an exciting and critical time for the UK pharmaceutical industry as we face up to a number of challenges, in particular addressing life outside of the European Union.

“It’s important that the ABPI can provide a coherent and aligned voice for our industry which represents the views of companies large and small.”

The trade association said it now represents nine out of 10 of the world’s largest pharmaceutical companies.

By Selina McKee

Source: Pharma Times

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]